Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC raised its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 2.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 608,416 shares of the company’s stock after purchasing an additional 11,985 shares during the quarter. Kiniksa Pharmaceuticals International accounts for approximately 1.6% of Rice Hall James & Associates LLC’s portfolio, making the stock its 13th largest position. Rice Hall James & Associates LLC owned about 0.79% of Kiniksa Pharmaceuticals International worth $29,295,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Amundi acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares in the last quarter. Millennium Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Creative Planning purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $358,000. Finally, Quantbot Technologies LP purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $43,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Canaccord Genuity Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. The Goldman Sachs Group upped their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and an average price target of $68.00.

Insider Buying and Selling

In related news, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the transaction, the chief executive officer owned 48,565 shares in the company, valued at $2,623,481.30. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at $628,554.60. This trade represents a 51.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 628,427 shares of company stock worth $32,833,228. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $62.84 on Friday. The stock’s 50-day moving average is $56.87 and its two-hundred day moving average is $49.97. Kiniksa Pharmaceuticals International, plc has a 1-year low of $26.27 and a 1-year high of $67.53. The company has a market cap of $4.83 billion, a price-to-earnings ratio of 69.82 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 EPS. Equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.25 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.